Factors influencing the initial glycemic efficacy of dorzagliatin, a novel glucokinase activator, in type 2 diabetes.

Abstract

Purpose: To investigate the potential factors influencing blood glucose levels in patients with type 2 diabetes (T2DM) during the initial administration of dorzagliatin.

Methods: In this study, we enrolled 173 hospitalized patients diagnosed with T2DM who received dorzagliatin treatment. The mean fasting blood glucose (MFBG) and mean postprandial blood glucose (MPBG) were determined by recording the fasting and 2-h postprandial blood glucose for three consecutive days following dorzagliatin administration. Comprehensive data were collected, including demographic characteristics, anthropometric measurements, metabolic profiles, organ function parameters, and detailed information on glucose-lowering medications. Multiple linear regression analysis was utilized to identify independent predictors of MFBG and MPBG.

Results: MFBG in T2DM patients treated with dorzagliatin was positively correlated with the duration of diabetes (β = 0.241, P = 0.002), baseline fasting plasma glucose (FPG) (β = 0.198, P = 0.010), and total cholesterol (TC) (β = 0.166, P = 0.036). MPBG was negatively associated with metformin use (β = -0.286, P = 0.012), and the risk of hypoglycemia was also associated with metformin use (OR = 4.25, P = 0.021) rather than insulin or other antidiabetic agents. In addition, MPBG was positively related to the duration of diabetes (β = 0.204, P = 0.008), and aspartate aminotransferase (AST) (β = 0.186, P = 0.008).

Conclusion: Blood glucose levels of T2DM patients during dorzagliatin initial treatment are positively correlated with diabetes duration, suggesting greater efficacy of dorzagliatin in patients with shorter disease duration. Metformin may enhance the glucose-lowering efficacy of dorzagliatin but also increase the risk of hypoglycemia. Furthermore, factors like baseline FPG, TC and AST also influence outcomes.